{"doc_id": "33031652", "type of study": "Therapy", "title": "", "abstract": "Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.\nHydroxychloroquine and chloroquine have been proposed as treatments for coronavirus disease 2019 (Covid-19) on the basis of in vitro activity and data from uncontrolled studies and small, randomized trials.\nIn this randomized, controlled, open-label platform trial comparing a range of possible treatments with usual care in patients hospitalized with Covid-19, we randomly assigned 1561 patients to receive hydroxychloroquine and 3155 to receive usual care.\nThe primary outcome was 28-day mortality.\nThe enrollment of patients in the hydroxychloroquine group was closed on June 5, 2020, after an interim analysis determined that there was a lack of efficacy.\nDeath within 28 days occurred in 421 patients (27.0%) in the hydroxychloroquine group and in 790 (25.0%) in the usual-care group (rate ratio, 1.09; 95% confidence interval [CI], 0.97 to 1.23; P\u2009=\u20090.15).\nConsistent results were seen in all prespecified subgroups of patients.\nThe results suggest that patients in the hydroxychloroquine group were less likely to be discharged from the hospital alive within 28 days than those in the usual-care group (59.6% vs. 62.9%; rate ratio, 0.90; 95% CI, 0.83 to 0.98).\nAmong the patients who were not undergoing mechanical ventilation at baseline, those in the hydroxychloroquine group had a higher frequency of invasive mechanical ventilation or death (30.7% vs. 26.9%; risk ratio, 1.14; 95% CI, 1.03 to 1.27).\nThere was a small numerical excess of cardiac deaths (0.4 percentage points) but no difference in the incidence of new major cardiac arrhythmia among the patients who received hydroxychloroquine.\nAmong patients hospitalized with Covid-19, those who received hydroxychloroquine did not have a lower incidence of death at 28 days than those who received usual care. (Funded by UK Research and Innovation and National Institute for Health Research and others; RECOVERY ISRCTN number, ISRCTN50189673; ClinicalTrials.gov number, NCT04381936.).\nCopyright \u00a9 2020 Massachusetts Medical Society.\n", "Evidence Map": {"Enrollment": [{"term": "Hospitalized Patients", "negation": "affirmed", "UMLS": {}, "start": 32, "end": 53}, {"term": "Covid-19", "negation": "affirmed", "UMLS": {}, "start": 59, "end": 67}, {"term": "hospitalized", "negation": "affirmed", "UMLS": {}, "start": 129, "end": 141}, {"term": "Covid-19", "negation": "affirmed", "UMLS": {}, "start": 147, "end": 155}, {"term": "mechanical ventilation", "negation": "negated", "UMLS": {}, "start": 43, "end": 65}, {"term": "hospitalized", "negation": "affirmed", "UMLS": {}, "start": 15, "end": 27}, {"term": "Covid-19", "negation": "affirmed", "UMLS": {}, "start": 33, "end": 41}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19 .", "Evidence Elements": {"Participant": [{"term": "Hospitalized Patients", "negation": "affirmed", "UMLS": {}, "start": 32, "end": 53}, {"term": "Covid-19", "negation": "affirmed", "UMLS": {}, "start": 59, "end": 67}], "Intervention": [{"term": "Hydroxychloroquine", "negation": "affirmed", "UMLS": {}, "start": 10, "end": 28}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "Hydroxychloroquine and chloroquine have been proposed as treatments for coronavirus disease 2019 ( Covid-19 ) on the basis of in vitro activity and data from uncontrolled studies and small , randomized trials .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "In this randomized , controlled , open-label platform trial comparing a range of possible treatments with usual care in patients hospitalized with Covid-19 , we randomly assigned 1561 patients to receive hydroxychloroquine and 3155 to receive usual care .", "Evidence Elements": {"Participant": [{"term": "hospitalized", "negation": "affirmed", "UMLS": {}, "start": 129, "end": 141}, {"term": "Covid-19", "negation": "affirmed", "UMLS": {}, "start": 147, "end": 155}], "Intervention": [{"term": "usual care", "negation": "affirmed", "UMLS": {}, "start": 106, "end": 116}, {"term": "hydroxychloroquine", "negation": "affirmed", "UMLS": {}, "start": 204, "end": 222}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The primary outcome was 28-day mortality .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "28-day mortality", "negation": "affirmed", "UMLS": {}, "start": 24, "end": 40}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "The enrollment of patients in the hydroxychloroquine group was closed on June 5 , 2020 , after an interim analysis determined that there was a lack of efficacy .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "hydroxychloroquine", "negation": "affirmed", "UMLS": {}, "start": 34, "end": 52}], "Outcome": [], "Observation": [{"term": "lack", "negation": "affirmed", "UMLS": {}, "start": 143, "end": 147}], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "Death within 28 days occurred in 421 patients ( 27.0 % ) in the hydroxychloroquine group and in 790 ( 25.0 % ) in the usual-care group ( rate ratio , 1.09 ; 95 % confidence interval [ CI ] , 0.97 to 1.23 ; P=0.15 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "hydroxychloroquine", "negation": "affirmed", "UMLS": {}, "start": 64, "end": 82}, {"term": "usual-care", "negation": "affirmed", "UMLS": {}, "start": 118, "end": 128}], "Outcome": [{"term": "Death within 28 days", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 20}], "Observation": [], "Count": [{"term": "421 patients ( 27.0 % )", "negation": "affirmed", "UMLS": {}, "start": 33, "end": 56}, {"term": "790 ( 25.0 % )", "negation": "affirmed", "UMLS": {}, "start": 96, "end": 110}]}, "Evidence Propositions": [{"Intervention": "hydroxychloroquine", "Observation": "", "Count": "421 patients ( 27.0 % )", "Outcome": "Death within 28 days"}, {"Intervention": "usual-care", "Observation": "", "Count": "790 ( 25.0 % )", "Outcome": "Death within 28 days"}]}, {"Section": "RESULTS", "Text": "Consistent results were seen in all prespecified subgroups of patients .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "all", "negation": "affirmed", "UMLS": {}, "start": 32, "end": 35}], "Outcome": [], "Observation": [{"term": "Consistent results", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 18}], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "The results suggest that patients in the hydroxychloroquine group were less likely to be discharged from the hospital alive within 28 days than those in the usual-care group ( 59.6 % vs . 62.9 % ; rate ratio , 0.90 ; 95 % CI , 0.83 to 0.98 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "hydroxychloroquine", "negation": "affirmed", "UMLS": {}, "start": 41, "end": 59}, {"term": "usual-care", "negation": "affirmed", "UMLS": {}, "start": 157, "end": 167}], "Outcome": [{"term": "discharged from the hospital alive within 28 days", "negation": "affirmed", "UMLS": {}, "start": 89, "end": 138}], "Observation": [{"term": "less likely", "negation": "affirmed", "UMLS": {}, "start": 71, "end": 82}, {"term": "59.6 %", "negation": "affirmed", "UMLS": {}, "start": 176, "end": 182}, {"term": "62.9 %", "negation": "affirmed", "UMLS": {}, "start": 188, "end": 194}], "Count": []}, "Evidence Propositions": [{"Intervention": ["hydroxychloroquine", "usual-care"], "Observation": "less likely", "Outcome": "discharged from the hospital alive within 28 days", "Count": ""}]}, {"Section": "RESULTS", "Text": "Among the patients who were not undergoing mechanical ventilation at baseline , those in the hydroxychloroquine group had a higher frequency of invasive mechanical ventilation or death ( 30.7 % vs . 26.9 % ; risk ratio , 1.14 ; 95 % CI , 1.03 to 1.27 ) .", "Evidence Elements": {"Participant": [{"term": "mechanical ventilation", "negation": "negated", "UMLS": {}, "start": 43, "end": 65}], "Intervention": [{"term": "hydroxychloroquine", "negation": "negated", "UMLS": {}, "start": 93, "end": 111}], "Outcome": [{"term": "frequency of invasive mechanical ventilation or death", "negation": "negated", "UMLS": {}, "start": 131, "end": 184}], "Observation": [{"term": "higher", "negation": "negated", "UMLS": {}, "start": 124, "end": 130}, {"term": "30.7 %", "negation": "affirmed", "UMLS": {}, "start": 187, "end": 193}, {"term": "26.9 %", "negation": "affirmed", "UMLS": {}, "start": 199, "end": 205}], "Count": []}, "Evidence Propositions": [{"Intervention": [], "Observation": "higher", "Outcome": "", "Count": ""}]}, {"Section": "RESULTS", "Text": "There was a small numerical excess of cardiac deaths ( 0.4 percentage points ) but no difference in the incidence of new major cardiac arrhythmia among the patients who received hydroxychloroquine .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "incidence of new major cardiac arrhythmia", "negation": "negated", "UMLS": {}, "start": 104, "end": 145}], "Observation": [{"term": "small numerical excess of cardiac deaths", "negation": "affirmed", "UMLS": {}, "start": 12, "end": 52}, {"term": "percentage points", "negation": "affirmed", "UMLS": {}, "start": 59, "end": 76}, {"term": "difference", "negation": "negated", "UMLS": {}, "start": 86, "end": 96}], "Count": []}, "Evidence Propositions": [{"Intervention": [], "Observation": "difference", "Outcome": "incidence of new major cardiac arrhythmia", "Count": ""}]}, {"Section": "CONCLUSIONS", "Text": "Among patients hospitalized with Covid-19 , those who received hydroxychloroquine did not have a lower incidence of death at 28 days than those who received usual care . ( Funded by UK Research and Innovation and National Institute for Health Research and others ; RECOVERY ISRCTN number , ISRCTN50189673 ; ClinicalTrials.gov number , NCT04381936 . ) .", "Evidence Elements": {"Participant": [{"term": "hospitalized", "negation": "affirmed", "UMLS": {}, "start": 15, "end": 27}, {"term": "Covid-19", "negation": "affirmed", "UMLS": {}, "start": 33, "end": 41}], "Intervention": [{"term": "hydroxychloroquine", "negation": "affirmed", "UMLS": {}, "start": 63, "end": 81}, {"term": "usual care", "negation": "affirmed", "UMLS": {}, "start": 157, "end": 167}], "Outcome": [{"term": "incidence of death at 28 days", "negation": "negated", "UMLS": {}, "start": 103, "end": 132}], "Observation": [{"term": "lower", "negation": "negated", "UMLS": {}, "start": 97, "end": 102}], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Copyright \u00a9 2020 Massachusetts Medical Society .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}